The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands by Southan, Christopher et al.
D1054–D1068 Nucleic Acids Research, 2016, Vol. 44, Database issue Published online 12 October 2015
doi: 10.1093/nar/gkv1037
The IUPHAR/BPS Guide to PHARMACOLOGY in 2016:
towards curated quantitative interactions between
1300 protein targets and 6000 ligands
Christopher Southan1,†, Joanna L. Sharman1,†, Helen E. Benson1,†, Elena Faccenda1,†,
Adam J. Pawson1,†, Stephen P. H. Alexander2, O. Peter Buneman3, Anthony P. Davenport4,
John C. McGrath5, John A. Peters6, Michael Spedding7, William A. Catterall8,
Doriano Fabbro9, Jamie A. Davies1,* and NC-IUPHAR
1Centre for Integrative Physiology, University of Edinburgh, Edinburgh, EH8 9XD, UK, 2School of Biomedical
Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK, 3Laboratory for Foundations of
Computer Science, School of Informatics, University of Edinburgh, Edinburgh, EH8 9LE, UK, 4Clinical Pharmacology
Unit, University of Cambridge, Cambridge, CB2 0QQ, UK, 5School of Life Sciences, University of Glasgow, Glasgow,
G12 8QQ, UK, 6Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School,
University of Dundee, Dundee, DD1 9SY, UK, 7Spedding Research Solutions SARL, Le Ve´sinet 78110, France,
8Department of Pharmacology, University of Washington, Seattle, WA 98195-7280, USA and 9PIQUR Therapeutics,
Basel 4057, Switzerland
Received September 07, 2015; Revised September 25, 2015; Accepted September 29, 2015
ABSTRACT
The IUPHAR/BPS Guide to PHARMACOLOGY
(GtoPdb, http://www.guidetopharmacology.org) pro-
vides expert-curated molecular interactions between
successful and potential drugs and their targets
in the human genome. Developed by the Interna-
tional Union of Basic and Clinical Pharmacology
(IUPHAR) and the British Pharmacological Society
(BPS), this resource, and its earlier incarnation as
IUPHAR-DB, is described in our 2014 publication.
This update incorporates changes over the interven-
ing seven database releases. The unique model of
content capture is based on established and new tar-
get class subcommittees collaborating with in-house
curators. Most information comes from journal arti-
cles, but we now also index kinase cross-screening
panels. Targets are specified by UniProtKB IDs. Small
molecules are defined by PubChem Compound Iden-
tifiers (CIDs); ligand capture also includes peptides
and clinical antibodies. We have extended the cap-
ture of ligands and targets linked via published quan-
titative binding data (e.g. Ki, IC50 or Kd). The resulting
pharmacological relationship network now defines
a data-supported druggable genome encompassing
7% of human proteins. The database also provides an
expanded substrate for the biennially published com-
pendium, the Concise Guide to PHARMACOLOGY.
This article covers content increase, entity analysis,
revised curation strategies, new website features and
expanded download options.
INTRODUCTION
As demonstrated by this journal special issue, open
databases have become indispensable for pharmacology,
drug discovery, metabolism and chemical biology, and are
increasingly important across other biomedical domains.
The amount of structural information now freely avail-
able is immensely useful to researchers, but navigating the
resources is becoming problematic for database users (1).
UniChem and PubChem now exceed 90 and 60 million en-
tries respectively, with nearly 14 million structures added
in 2014 alone (2,3). Of these, however, only 0.4% have
been tested experimentally. Thus, while just over 2 mil-
lion of the current PubChem compounds have BioAssay
results (with ≈50% tagged as active) (4), the increase in
submitted structures is accelerating way beyond the com-
munity capacity to generate bioactivity measurements, ex-
tract themmanually from papers and patents, crowd-source
representations for structural correctness, or to curate syn-
onym mappings. This cheminformatics problem is analo-
gous to the situation in bioinformatics, where the gap be-
tween the generation of new protein sequences and the
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experimental assignment of at least some level of biolog-
ical function is inexorably widening. For example, while
UniProtKB/TrEMBL has mushroomed to nearly 50 mil-
lion entries, only just over 0.5 million entries have sup-
porting evidence for the UniProtKB/Swiss-Prot level of ex-
pert annotation (5). While the analogy should not be taken
too far, the IUPHAR/BPS Guide to PHARMACOL-
OGY (GtoPdb, http://www.guidetopharmacology.org; (6))
has some conceptual overlap with Swiss-Prot in that we
also seek to maximise the level of data support within our
‘small data’ resource, to underpin the exploitation of ‘big
data’.We thus continue to focus our curatorial capacity on a
high-quality, annotated subset of human targets with quan-
titative ligand relationships. These are selected as being the
most relevant to contemporary pharmacology and future
drug discovery. From its origins in 2011, GtoPdb has be-
come recognized for the following:
 Providing an authoritative and web-browsable synopsis
of drug targets and drugs (approved, clinical or research);
 Being an accurate and continually expanding source
of information for molecular mechanisms of action
(MMOA) of pharmacological agents;
 Facilitating selection of appropriate selective compounds
for in vitro and in vivo experimentation;
 Providing a hierarchical organization of receptors, chan-
nels, transporters, enzymes and other drug targets ac-
cording to their molecular relationships and physiolog-
ical functions;
 Incorporating nomenclature recommendations from the
International Union of Basic and Clinical Pharmacology
(IUPHAR) Committee on Receptor Nomenclature and
Drug Classification (NC-IUPHAR);
 Utilising a network of NC-IUPHAR subcommittees,
comprising over 600 domain experts, to guide ligand and
target annotation;
 Inclusion of reciprocal links to key genomic, protein and
small molecule resources;
 Monitoring the de-orphanization of molecular targets,
particularly receptors;
 Disseminating NC-IUPHAR-derived standards and ter-
minology in quantitative pharmacology;
 Offering advanced query and data mining;
 Providing a variety of downloadable data sets and format
options;
 As the source for the biennially published Concise Guide
to PHARMACOLOGY compendium;
 Being an educational resource for researchers, students
and the public.
The sections below will expand on these aspects, focusing
on changes since our 2014 publication (6).
CONTENT EXPANSION
Targets
Our generic use of the term ‘target’ refers to a record in
the database that has been resolved to a UniProtKB/Swiss-
Prot ID as our primary identifier. Reasons for this choice
include (i) the Swiss-Prot canonical philosophy of protein
annotation, (ii) species specificity and (iii) global recipro-
Table 1. Target class content
Targets UniProt ID count
7TM receptors* 395
Nuclear hormone receptors 48
Catalytic receptors 239
Ligand-gated ion channels 84
Voltage-gated ion channels 141
Other ion channels 47
Enzymes (all) 1164
Transporters 508
Kinases 539
Proteases 240
Other proteins 135
Total number of targets 2761
*Not all our 7TM receptor records are unequivocally assigned as GPCRs,
but for convenience we refer to these generally as GPCRs in the text.
cal cross-referencing. Notwithstanding, target records also
include RefSeq protein IDs and genomic IDs from En-
trez Gene, HGNC and Ensembl. Because NC-IUPHAR
oversees the nomenclature of (particularly) receptors and
channels, these human protein classes are complete in
GtoPdb (with the exception of the olfactory and opsin-
type GPCRs). The G protein-coupled receptors (GPCRs),
ion channels and nuclear hormone receptors (NHRs) were
present in the earliest database versions, regardless of the
level of molecular pharmacology that could be assigned
to them at that time, although they were obviously cho-
sen because they were drug-target rich. By 2012, the cat-
alytic receptors and transporters had been added. At the
end of 2012we received a Biomedical ResourcesGrant from
the UKWellcome Trust with the objective of capturing the
likely targets of future medicines (i.e. to cover the data-
supported druggable genome). We consequently embarked
on a major expansion of protein capture, of which enzymes
formed the largest part. The current category counts are
shown in Table 1 (note that statistics of all content types
specified throughout this paper refer to our database release
2015.2 from August 2015).
The total number of targets in Table 1 represents 14% of
the current Swiss-Prot human protein count of 20,204; al-
though not all our entries are yet mapped to ligands. While
the database is centred on human proteins, information
frommouse and rat are also presented because rodent bind-
ing data are the most common type encountered in papers,
either in addition to or instead of, human data. We thus
currently have 6929 human proteins and rat and mouse or-
thologues (i.e. 84% of a maximum projected three-species
count). The 16% shortfall is because either, some do not yet
have Swiss-Prot IDs (i.e. are TrEMBL only) or, our curation
indicates the orthology relationships aremore complex than
the 1:1 case.
Since our 2014 NAR publication, expansion has focused
on new families that have a significant density of ligand
mappings and drug target interest. We have not yet in-
cluded all 523 proteases (as counted in human Swiss-Prot
by the intersect of hydrolase function with a MEROPS (7)
cross-reference), opting instead for a ligand-driven expan-
sion in the first instance. For the kinome, all 539 entries
(selected by our NC-IUPHAR kinase subcommittee) were
pre-loaded because of the inclusion of matrix screens (see
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Figure 1. Hierarchical listing for the ion channel families and subfamilies.
below) and proposals to complete tool compound coverage
(8,9). We continue to add ligand mappings for both these
large target classes (supported by the NC-IUPHAR pro-
tease and kinase subcommittees). Users can access data for
each of the nine target classes in Table 1 via the GtoPdb
website. The ion channel hierarchy is shown as an exam-
ple (Figure 1). Where possible we adhere to the HGNC
(10) Gene Families Index (http://www.genenames.org/cgi-
bin/genefamilies/), but there are instances where the NC-
IUPHAR classification deviates from these (e.g. catalytic
receptors).
In the database, the term ‘target’ includes verified tar-
gets for the MMOAs for drugs used to treat human dis-
eases, newer receptor-ligand pairings judged to be credi-
ble by a dedicated NC-IUPHAR subcommittee (11), and
human targets identified by orthologue activity mapping
where only non-human binding data are available. Exam-
ples of the latter category include the first generation of ap-
proved Angiotensin-converting enzyme (ACE) inhibitors,
such as moexiprilat, for which only the rabbit protein has
documented quantitative pharmacology. In addition, the
database contains the targets of undesirable ligand inter-
actions (sometimes termed ‘anti-targets’), for example the
HERG channel, Kv11.1 (KCNH2) as a liability target for
cardiac toxicity from the withdrawn drug terfenadine. Tar-
get capture also extends to emergent targets––proteins that
do not have sufficient validation data to be considered bona
fide therapeutic drug targets, but are nonetheless being in-
vestigated to both establish their normal function and pos-
sible disease involvement. Cathepsin A (CTSA) is an in-
teresting recent example, because not only is compound
8a [PMID 22861813] being explored to treat cardiac hy-
pertrophy, but also an approved antiviral drug telaprevir is
now being investigated for repurposing as a Cathepsin A
inhibitor.
Target statistics
One of the benefits of our recently enhanced curation is that
it enables more detailed exploration of statistics of database
content. This gives us a detailed overview of the database
and allows us to compare it with other resources, to com-
municate results to users and funders, to measure progress
and identify areas for future expansion. Target-centric ex-
amples of such statistics are shown in Figure 2.
While the top-level GO categories are relatively coarse
and not exclusive (e.g. some proteins are under both binding
and enzymes), they provide a straightforward visual assess-
ment of differences between protein sets. Not surprisingly,
the curated set of ligand-binding targets (set B in Figure 2),
compared to the whole proteome (set A in Figure 2), is en-
riched for receptors, enzymes and transporters. By select-
ing only targets of approved drugs (set C in Figure 2) we
see a similar pattern to set B, but a proportional increase
of both receptors and channels at the expense of enzymes.
These results provide detailed insights into relationship dis-
tributions as well as the current state of pharmacology and
therapeutics. Such analyses can be extended by many lev-
els of detail to include other approaches (e.g. UniProtKB
indexing and cross-referencing).
Ligands
In the GtoPdb context, the term ‘ligand’ is used mostly
for small molecule-to-large molecule interactions but it
does extend to selected protein-protein interactions (e.g.
cytokines-to-receptors or antibodies-to-cytokines). Inter-
actions are selected for curation because they meet most of
the following criteria:
1. mediated by direct binding (i.e. thermodynamically
driven);
2. interaction is specific (i.e. reported cross-reactivity does
not indicate promiscuity);
3. have experimentally measured quantitative binding-
related results;
4. modulate the activity of their targets with biochemical
consequences;
5. have distinct pharmacologically-relevant effects (even if
unknown MMOAs);
6. related to drug discovery research for human disease;
7. published descriptions are resolvable to molecular struc-
tures;
8. reported in vitro potencies are judged to be mechanisti-
cally relevant to in vivo pharmacology (i.e. usually below
1 M).
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Figure 2. High level Gene Ontology (GO) functional categories for three sets of human proteins. Set A was generated from the total proteome of 20,204.
Set B represents the 1228 targets with quantitative ligand binding data in GtoPdb. Set C represents the 554 targets where at least one approved drug is
included in the ligand binding data. Panel D provides the colour key to the top-level GO categories. The charts were generated by loading Swiss-Prot IDs
from the protein sets into the PANTHER Gene List Analysis Tool (55).
Our classification is divided into endogenous ligands (e.g.
metabolites, hormones, neurotransmitters and cytokines)
and exogenous ligands (e.g. drugs, research leads, toxins and
probe compounds). Since our 2014 publication, the increase
has been mainly driven by target-centric expansion (i.e. via
target-to-ligand curation), but we have also focused on the
following ligand selections (i.e. ligand-to-target curation)
because of strong user interest:
 approved drugs;
 clinical development candidates (typically Phase 1 or be-
yond);
 approved or clinically-trialled monoclonal antibodies
(i.e. with International Nonproprietary Names (INNs));
 compounds from repurposing initiatives (e.g. the Na-
tional Center for Advancing Translational Sciences and
Medical Research Council);
 epigenetic and kinase probes from the Structural Ge-
nomics Consortium;
 representative compounds directed against reported
Alzheimer’s Disease (AD) targets;
 R&D portfolio compounds associated with journal pa-
pers and/or repurposing documentation from selected
companies (e.g. AstraZeneca);
 new human Protein Data Bank (PDB) (12,13) ligand
structures;
 review articles with high density of relevant ligand-to-
protein relationships;
 ligands highlighted in new papers of particular interest
but outside the categories above, to whichwewere alerted
by NC-IUPHAR subcommittee members, the GtoPdb
team or Twitter notifications.
Ligand lists are displayed in nine categories and can be
accessed at http://www.guidetopharmacology.org/GRAC/
LigandListForward. Current counts for each of these cat-
egories are provided in Table 2.
PubChem content
Since our 2014 publication, we have adopted the PubChem
Compound ID (CID) as our primary small-molecule identi-
fier and we refresh our own ligands as PubChem Substance
Identifiers (SIDs) for each release. This means we (and, im-
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Table 2. Ligand category counts. SID refers to the PubChem Substance
Identifier and CID the PubChem Compound Identifier
Ligand classification Count
Synthetic organics 5055
Metabolites 582
Endogenous peptides 759
Other peptides including synthetic peptides 1222
Natural products 234
Antibodies 138
Inorganics 34
Approved drugs 1233
Withdrawn drugs 67
Ligands with INNs 1882
Isotopically labelled ligands 593
PubChem CIDs 6037
PubChem SIDs 8024
Total number of ligands 8024
portantly, anyone else) can generate a detailed analysis of
our content (14,15). This provides uniquely high-resolution
breakdowns for a wide range of categories, sources and
properties, and these can be selected for their chemical
and/or biological annotation types. The distributions for a
selection of these are shown in Figure 3.
We aim to complete a PubChem re-submission within
two weeks of our public releases. Our SIDs are then merged
into CIDs according to the PubChem chemistry rules (Fig-
ure 3, Rows 1 and 2). The excess of SIDs over CIDs re-
flects those SIDs that do not have chemical structure repre-
sentable in SMILES format (i.e. cannot form CIDs). Most
of these are large peptides or small proteins but also in-
clude our antibody entries. We also revise a small number
of entries between our release re-submissions. As expected,
since it is our major curation source, over 90% of struc-
tures can be linked to a PubMed ID either via Entrez or
ChEMBL (Figure 3, Row 3). For patent extractionmatches,
a filter was made from the three PubChem sources (IBM,
SCRIPDB and SureChEMBL) that use automated Chem-
ical Named Entity Recognition and include patent docu-
ment numbers in the CID records. At 78% (Figure 3, Row
4), this is much higher than in 2013 due to the increase
in patent chemistry in PubChem (16). While our matches
overlap ChEMBL by 76% (Figure 3, Row 5), we have 1361
structures not in this source. The proportion of CIDs hav-
ing a match to at least one chemical vendor SID has risen
to 72% (Figure 3, Row 6). Another filter was used as the
Lipinski Rule-of-Five (ROF) with an extended molecular
weight (Mw) range. Thus, 70% of our structures are inside
this medicinal chemistry property ‘sweet zone’ that encom-
passes both drugs and leads (Figure 3, Row 7). The BioAs-
say matches (Figure 3, Row 8) coincide with the ChEMBL
count at 70% but are complementary because of extended
connectivity to data sets from the Molecular Libraries ini-
tiative (3).
Just 30% of our CIDs have a match to the MeSH term
‘Pharmacological Actions’ (Figure 3, Row 9), which means
the compound has been assigned pharmacological in vivo
mechanisms of action by MeSH curators based on the pa-
per in which it was reported. This total is surprisingly low
and indicates a capture gap for this MeSH category. We
recorded a 25% intersect of our compounds with the 10,939
CIDs retrieved by the query ‘INN (or) USAN’ which rep-
resent non-proprietary names for either approved drugs or
failed clinical candidates (Figure 3, Row 10). The number
of GtoPdb ligands with a match to PDB structures is 17%
(Figure 3, Row 11). The 335 CIDs unique to us in PubChem
(Figure 3, Row 12) include compounds extracted from doc-
uments, either before they might appear from other sub-
mitters, or curated from journals not extracted by other
sources. The designation of radiolabelled ligands inGtoPdb
presents a curatorial challenge because for 467 entries, the
publications we have curated do not specify the exact substi-
tution position for the radioisotope. Consequently, we only
have 118 CIDs (Figure 3, Row 13) where this was defined by
the authors. Because of strong interest in these compounds
as pharmacological tools, we have had to re-use the unmod-
ified structure (thereby effectively generating a duplicate) in
order to explicitly link the radiolabelled compound names
to the published experiments.
A caveat associated with the statistics in Figure 3 arises
from the numbers being CID ‘exact match’ results (i.e.
equivalent to a full InChI-to-InChI match). For individual
cases, users can either use the PubChem ‘same connectivity’
operator to reveal structures with the same carbon skeleton
or, from our pages, execute a Google search with either the
full InChIKey or just the core layer. Thus, most commonly
in terms of salt forms or different stereoisomer representa-
tions of the same core structure, our CIDs may have addi-
tional matches (i.e. be the same compound in pharmacolog-
ical terms) in source entries other than those counted above
(but with different CIDs).
Interaction mapping
Quantitative ligand-to-protein interaction mappings con-
stitute the core of the database. Curated relationship data
across all targets is shown in Table 3. The total number
of references in GtoPdb has reached 27880, a figure that
includes the many target-specific references we also cap-
ture. Most (98%) have PubMed IDs but we include a few
other reference types judged to be sufficiently provenanced.
These include journals not indexed in PubMed, patents,
slide sets, meeting abstracts, confirmed PubChem BioAs-
says and pharmaceutical company open information sheets
for (unpublished) repurposing candidates.
Kinases
In 2013, we added three published sets of results from cross-
screening of kinase panels, to extend data for this important
target class (17–19). The cumulative set of 406 kinases x 230
ligands includes 158551 data points for users to inspect. An
example from the imatinib entry is shown in Supplementary
Figure S1.
The constitutive problem with surfacing panel screens
in a database is that the assays are balanced to produce
mostly negative results (i.e. compounds will be predomi-
nantly inactive at the threshold tested). In addition, theMil-
lipore and Reaction Biology sets measure only percentage-
activity-remaining at fixed concentrations, rather than dose-
responses. For this reason, we separate the kinase panel re-
sults from the curated literature values (typically selected as
 at Periodicals D
ept on A
pril 5, 2016
http://nar.oxfordjournals.org/
D
ow
nloaded from
 
Nucleic Acids Research, 2016, Vol. 44, Database issue D1059
Figure 3. PubChem intersects. Figures were obtained via the PubChem interface using mostly pre-existing indexing. The exceptions are custom selects
(described below) for patents, INN or United States Adopted Names (USAN) and Lipinski Rule-of-Five (ROF) + 150–800 Mw. With the exception of the
SIDs (Row 1) intersects are CID counts. These queries were executed at the beginning of September 2015 when the PubChem CID total was 60.8 million
and our own SIDs from release 2015.2 had been processed.
Table 3. Interaction counts. Primary target indicates the dominant MMOA
Interaction type Count
Targets with ligand interactions 1505
Targets with quantitative ligand interactions 1228
Targets with approved drug interactions 554
Primary targets with approved drug interactions 312
Ligands with target interactions 6796
Ligands with quantitative interactions (approved drugs) 5860 (738)
Ligands with clinical use summaries (approved drugs) 1724 (1231)
Number of binding constants 44691
Number of binding constants curated from the literature 13484
active IC50 or Ki rather than Kd) in our data model and
mapping statistics. Users can see both in the web display
(Supplementary Figure S1; note that only the top 10 tar-
gets in each of the screens are displayed on the ligand page,
with the option to view the full set). As a cross-check, we
determined that 68 kinases in the DiscoveRx panel had a
pAct (pKd) value for a panel ligand at 7 or above (i.e. 100
nM or less). We had independently curated literature inhi-
bition values for each of these 68 (but not necessarily for the
same ligand and/or assay conditions) indicating there were
no high-potency kinase panel results for which we did not
also have curated data values.
Single versus multiple versus complex targets
As explained above, our capture of ligand-target relation-
ships is founded on citable activity data that define pharma-
cologically significant molecular interactions. We recently
enhanced our mapping precision by introducing the con-
cept of a primary target, identified with a tag, when the
publication record indicates that drug or lead has been opti-
mised for a single target. By implication, the in vitroMMOA
is likely to be causative for observed therapeutic effect in vivo
(e.g. the effect of perindoprilat in lowering blood pressure is
due to its substrate-competitive binding potency (IC50) of
1 nM against ACE). Nonetheless this assumption has to be
caveatedwhere in vivo target validation data are still pending
(e.g. via mouse KO and/or a clear genetic disease associa-
tion). The curator-assigned ‘primary target’ tags delineate
a concise drug-to-target set of 312 human proteins for ap-
proved drugs.
We are well aware of the challenges of setting curato-
rial stringencies for structure-to-activity-to-target mapping
(20). One aspect of increasing importance is polypharma-
cology, where evidence suggests that clinical efficacy is me-
diated by multiple MMOAs. The simplest examples are
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drugs designed as dual inhibitors, such as fasidotrilat (an
antihypertensive agent that acts on both ACE and NEP )
where data support our assignment of two primary target
relationships to the ligand. The situation is more complex
for kinase inhibitors where in vitro data indicate that cer-
tain clinically successful inhibitors have polypharmacologic
MMOAs (9). Nonetheless, for relationship curation it re-
mains difficult to define exactly which binding results are
causatively relevant or if their capture is useful for GtoPdb
data mining. For this reason, we capture non-primary in-
teractions but do not tag them explicitly as ‘secondary tar-
gets’. We thus generally leave the interpretations of signifi-
cance (e.g. efficacious polypharmacology, off-target interac-
tions or side effect liabilities) open. An example here would
be bosutinib which has 24 curated interactions: only one of
these is tagged as primary, while the others are recorded for
user interpretation. However, in cases where the pharmaco-
logical significance of off-(primary) target binding data is
clear we will add a curators comment.
For complex targets, we have again taken a parsimo-
nious approach (in line with the primary target concept)
in mapping to the minimal, rather than maximal, num-
ber of proteins, to increase data mining precision (21).
Examples here include the approved proteasome inhibitor
bortezomib and the clinical candidate gamma-secretase in-
hibitor begacestat. We have mapped the former just to one
subunit, beta type, 5 protein, for which there is evidence for
direct binding of the drug, rather than adding the 43 distinct
components of the proteasome endopeptidase complex into
our relationship matrix. Analogously, the latter inhibitor is
mapped just to presenilin 1 (PSEN1) rather than all five
components of the gamma secretase complex.
Relationship distribution
The recent expansion phase has been predominantly target-
centric. Consequently, the distribution of quantitative map-
pings to targets has become more long-tailed. As expected,
the average ligands-per-target fell from 11 to 8 as the tar-
get total extended from 844 to 1401. Our statistical analysis
of this distribution (results not shown) highlighted impor-
tant aspects. One of these is the need to control the occu-
pancy at the top end of the distribution. As two examples,
the dopamine D1 receptor has 19 agonists and 15 antag-
onists that include 17 approved drugs, whereas the kinase
VEGFR-2 (KDR) has 54 inhibitors, including 14 approved
drugs (two of which are antibodies). While we have not in-
troduced an upper limit for ligands-per-target, we would
clearly impose a high threshold (based on pharmacological
significance) in these cases, before adding new ligands. This
contrasts with targets in the tail of the distributionwhere the
threshold for adding new ligands remains low. For example,
transmembrane protease, serine 6 (TMPRSS6) only has a
single inhibitor (inhibitor 1 [Colombo et al., 2012]) so far,
but, because the protein has a loss-of-function Mendelian
disease association with iron deficiency anaemia, new func-
tional probes may be published. The ‘tailing’ effect is also
manifest in our numbers of 207 single-ligand targets in 2013
expanding to 637 in 2015.
Notwithstanding our emphasis on establishing connec-
tivity for data mining, we also capture compounds with
important pharmacological effects where the therapeutic
MMOA is unknown or remains equivocal. Perhaps the best
known approved drug example is lithium, but we also have
research compounds where curator comments indicate a
phenotypic read-out and/or pathway-mapping as a partial
MMOA (e.g. CCG-1423).
Entity growth
The figures in Table 4 record recent increases in entities and
selected attributes.
Since the last publication, the largest entity-type increase
has been antibodies. The next categories, in order of in-
crease, are approved drugs and PubChem entries. We have
added newCID links to older entities (i.e. more of the struc-
tures we already had are now assigned to CIDs). We have
also plotted the relationship metrics for a spread of release
versions, including the one preceding our 2014 publication
(Figure 4).
Three of the four relationships show steady growth but
the classification of primary targets of approved drugs
shows a flattening off. This was expected because the cura-
tion ofmost of these target relationships (for at least one ap-
proved drug) had been largely completed by the end of 2014.
Approved drug curation, including new approvals directed
against existing targets, continued in 2015 but the number
of new protein targets mapped was very low.
CURATION ENHANCEMENTS
Strategy
In collaboration with our target-family subcommittees, we
have enhanced our curation procedures, because they are
the primary determinant of database value. Crucially, this
includes deciding what to leave out as well as include, and
we have introduced more stringent filtering to maximise the
utility of our relationship matrix. However, while we make
use of established ontologies and terminologies where pos-
sible (e.g. see the disease section below), we do not apply
rigid rules for content capture. We instead make extensive
use of curators’ comments that allow us to bridge between
structured annotations (i.e. indexed in the database) and the
flexibility of unstructured text. For users, we can thus spec-
ify new (or low frequency edge-case) relationship types via
cross-pointers that are not formalised in the current schema
(we may decide later to accommodate these via new struc-
tured indexing, if enough examples and an external termi-
nology consensus appear). An illustration of this is where
we add ‘repurposing’ to ligand comments. The term is used
rather loosely in the literature but a simple text query re-
trieves a list of compounds, with particular interest to many
users, where we judged the mention in a publication as rel-
evant.
Another manifestation of curatorial flexibility is that we
will add ligands from the earliest reports of chemical modu-
lators for a novel target (possibly patent-only), even if these
are of such low potency and/or specificity as would be un-
publishable for a well-characterised target (e.g. surrogate
ligands for orphan receptors). We will add superior ligands
as they are published, but do not typically remove older
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Table 4. Content changes since our 2014 publication (6). Only those major categories that could be normalised for comparison between 2013 and 2015
are included
Oct 2013 2015 Percentage increase
Target protein IDs 2485 2761 11
Ligands total 6064 8024 32
Approved drugs 559 1233 121
Antibodies 10 138 1280
Peptides 1776 1981 12
Synthetic small molecules 3504 5055 44
PubChem SIDs 3107 8024 158
PubChem CIDs 2694 6037 124
Binding constants 41076 44691 9
References 21774 27880 28
Figure 4. Relationship growth since 2012. The first (left-most) chart shows the number of targets with curated ligand interactions while the second chart
includes only those targets that are supported by quantitative data. The third and fourth charts show the number of approved drugs with data-supported
targets and those that may be considered primary targets, respectively.
ligands with cited references. Another unique strategic as-
pect is the undertaking of rolling updates by the subcommit-
tees. This includes not only adding context to new relation-
ships, but also reviewing their physiological and molecular
aspects. Indeed, many of our users come to the database to
learn about target proteins of interest in terms of family re-
lationships and roles in different settings.
Approved drugs
Our grant objectives include annotating the targets of ap-
proved human medicines (i.e. currently not anti-infectives).
However, the task is complicated by variation in database
molecular structures for approved drugs (22). For this rea-
son, we have chosen a consensus approach whereby we se-
lect the PubChem CID supported by the most submitters
(i.e. has the SID ‘majority vote’). We realise this approach
is not infallible, but it does have pragmatic utility. Specifi-
cally, an exact chemical structure match between a majority
of sources (at least some of which are manually curated) is
more likely to be right than wrong. An example is provided
by vapiprost where theCID6918030we have selected as (Z)-
7-[(1R,2R,3S,5S) is supported by 13 SIDs, including that of
ChEMBL, the Food and Drug Administration (FDA) Sub-
stance Product Labelling entry, and is concordant with the
INN document as well as the CAS Registry No. 85505–64–
2. The alternative (E)-7-[(1R,2R,3S,5S) form is represented
by nine SIDs merged into CID 6436588. The PubChem
‘same connectivity’ relationships records 13 CIDs (i.e. 11
additional ones) with various permutations or absences of
the stereo specifications.
We have reached a current total of 1222 approved drugs
(including antibodies) for which we have been able to cu-
rate drug-to-target relationships, and this covers new FDA
approvals to 2Q 2015. This is lower that we might expect,
but there is no agreement on what the approved drug count
should be at the molecular level (sources indicate anywhere
between 1200 and 1600). This anomaly emphasises the com-
plexities associated with the concept of drug structure ‘cor-
rectness’.We use curatorial stringency to limit, as far as pos-
sible, consequences of different structural representations
of the same drugs and associated splitting of activity map-
pings.
Two examples illustrate this. Since drugs can have many
salt forms, we typically select the parent CID for our target
and activity mappings. This is not only because this usu-
ally corresponds to the INN name-to-structure mapping,
but for in vitro experiments the parent ion is usually the ac-
tive moiety. However, records in PubChem BioAssay and
USAN designations often map to salt forms. A second ex-
ample is where an approved drug is an enantiomeric mix-
ture (that does not interconvert in vivo), but assay data can
be mapped to three different molecular representations (i.e.
both the R and S isomers and the mixture or ‘flat’ form). In
this case, we assign the drug tag to themixture andmap data
to this. We then add cross-pointers to the CIDs for the R
and S if data have been specifically reported and mapped to
them. Well known examples are omeprazole as the mixture
and esomeprazole as the S isomer, as separately approved
drugs. We include both withdrawn and discontinued drugs
(the latter being generally superseded by newer drugs) to
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maximise our capture and cheminformatic analysis of drug
sets. The terms are not exclusive (i.e. a drug can be tagged
as both approved and withdrawn) but these can be filtered
out of queries if necessary.
For a number of reasons, we will not attempt to capture
all molecular entities approved for human use. The main
reason is because the database is focused on quantitative
molecular pharmacology, captured as a ligand-target rela-
tionship matrix to facilitate data navigation and mining. It
is thus not a pharmacopeia-type compendium (of which
many are available), because many substances approved for
medicinal purposes would negatively impact the precision
of our database if we mapped-in their molecular interac-
tions as ‘drugs’.We therefore exclude simple molecules such
as acetic acid, ethanol, urea and common inorganic salts.
We also omit nutraceuticals that are principally metabolites
(e.g. we do not target-map the DrugBank ‘approved drug’
entry for NADH that lists 144 targets).
Patent exploitation
While ourmain extraction source remains the peer-reviewed
literature, we increasingly exploit patents for their unique
data content in particular cases. This has become easier be-
cause of the ‘big bang’ in the recent open availability of over
15 million patent-extracted chemical structures in several
large PubChem sources (16). We cite medicinal chemistry
patents in two circumstances: (i) where potent and selective
ligands are patent-only or (ii) where documented structure
activity relationships (SAR) are particularly complemen-
tary to those from published articles from the same team
(e.g. because many more analogues have quantitative data
and synthesis descriptions). We generally link to patents
only from those pharmaceutical companies and academic
institutions with an established medicinal chemistry repu-
tation. An example of the value of patent data is shown in
Figure 5 for beta-site APP-cleaving enzyme 2 (BACE2).
The BACE2-selective inhibitors claimed specifically as
potential anti-diabetes compounds are, as far as we can de-
termine, the only public database instantiation of these ac-
tivity mappings (23). In this context, it is important to note
that ChEMBL does in fact map 574 compounds to human
BACE2 (target ID CHEMBL2525). However, these are all
BACE1 inhibitors extracted from journal articles that have
included BACE2 cross-screening results, since the first pa-
per specifying the use of BACE2 inhibition for diabetes used
a single BACE1 inhibitor and no medicinal chemistry pa-
pers have described BACE2-selective inhibitors. Thus, the
chemistry is captured in SureChEMBL and GtoPdb, but
not ChEMBL.
We have also been able to exploit patents as a source of
both primary sequence and target binding data. This has
been particularly useful for monoclonal antibodies and ex-
ogenous therapeutic proteins or peptides where these data
may be absent from journal articles. In these cases, the
patent sequence databases provide the entry point and we
can also add cross-references to the UniParc records (24).
DISEASE ONTOLOGY AND CLINICAL VARIANTS
Another major effort since our 2014 publication has been
the review and expansion of target-linked diseases and as-
sociated mutations (Figure 6). We used the tool ‘ZOOMA’
(http://www.ebi.ac.uk/fgpt/zooma/index.html) to map our
disease names to Disease Ontology (25) and Orphanet
Rare Disease Ontology (http://www.orphadata.org/cgi-bin/
inc/ordo orphanet.inc.php) terms, and now use standard-
ised disease names that, wherever possible, are linked to
synonyms (which may include more general names for spe-
cific subtypes) and entries on the Orphanet (26) and OMIM
(http://omim.org/) websites. Disease Ontology terms are
linked to the Ontobee browser (27) which provides contex-
tual visualisation. Diseases are linked to targets via ‘patho-
physiologies’ which describe the role of the target in the dis-
ease, possibly including drugs and side effects, as well as
disease-causing mutations. Mutation descriptions have also
been standardised within GtoPdb. Future releases will link
drugs to diseases via the clinical data tab (Figure 7) and pro-
vide new target-disease-drug navigation options. This will
not only allow users to browse and search using disease
names but also enable us to present disease pages containing
lists of associated targets and ligands. We also intend to re-
view our listings of single nucleotide polymorphism (SNP)
variants, many of which are disease-associated.
WEBSITE FEATURES
The following description includes some basic aspects for
context, but focuses on the most important features added
since the previous report. We have improved our help doc-
umentation and tutorials. This now includes a substantial
set of frequently asked questions (FAQs) at http://www.
guidetopharmacology.org/faq.jsp) that inform users on new
features and data types. Enhancements have been made to
the search tools to improve user experience of the website.
The quick search box at the top right of every page and
the advanced search pages for targets and ligands now in-
clude autocomplete functionality for target, target family
and ligand names. Users are able to click on the matched
name and go directly to the corresponding database page.
We have also added support for the recognition of special
characters such as Greek letters found in target names (e.g.
 opioid receptor). Our ligand structure search tool uses the
JavaScript chemical editorMarvin JS (ChemAxon Limited,
Hungary), which replaces the Java applet version and offers
cross-platform compatibility including for tablets and mo-
bile devices. Searches now cover more database fields which
allows, for example, searches by disease name to retrieve as-
sociated targets and ligands.
As well as providing a variety of ways to search the
database (e.g. name, keyword, database identifier or ligand
structure), users can browse target and ligand lists accord-
ing to their biological or chemical classification. To deal
with the increasing size of the database and intersecting
classifications for some targets (e.g. EC 3.4 and protease)
we have introduced a hierarchical organisation. Targets are
grouped into families and subfamilies and visualised as
a navigable HTML tree with expandable and collapsible
nodes (see Figure 1 for example). Each family has a linked
database page including an overview, background reading
and details of subfamilies or individual family member pro-
teins. Alternatively, users may browse lists of ligands organ-
ised by chemical class or drug approval status. We have in-
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Figure 5. Inhibitors table from the detailed view of the BACE2 target entry, with the inclusion of five lead compounds from patents.
Figure 6. Clinically-Relevant Mutations and Pathophysiology for Kv7.1.
troduced a new category of labelled ligands for those with
radioactive incorporation or a fluorescent moiety. Labelled
ligands are also indicated within bioactivity data tables us-
ing a new symbol. We have also added two other new sym-
bols to bioactivity tables to indicate where the ligand is an
approved drug, and (as described above) where the target
can be considered the primary data-supported target of that
ligand. Furthermore, the information curated in support of
new interactions has been expanded to include affinity data
and details of the assay used, accessible in the bioactivity
table by clicking on the arrow at the right (e.g. see the entry
for ligand ‘example 20 (WO2010128058)’ in Figure 4).
Our grant mandate to curate the MMOAs of approved
drugs and clinical candidates has led to the introduction
of various new features on the ligand pages. A new ‘clini-
cal data’ tab provides summaries of clinical use, MMOA,
as well as absorption, distribution, metabolism and excre-
tion (ADME) data (Figure 7). Drug approval status is indi-
cated along with the FDA and EuropeanMedicines Agency
(EMA) first approval dates (a small number of drugs ap-
proved only in Japan are also included). INN compounds
now have on-the-fly name searches of PubMed titles, ab-
stracts and clinical trials. In addition, small molecules have
InChIKey searches of Google for exact or backbone chem-
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Figure 7. Clinical data summary tab for the approved drug telmisartan.
ical structure matches to many databases and chemical ven-
dors (28).
CONNECTIVITY COLLABORATIONS
We manually curate out-links to other databases that we
judge as having utility for a significant fraction of users.
This applies both for navigation and computational mining
across linked data. For this reason, we continually review
out-links and monitor the status of reciprocal in-links (but
note there may also be in-links of which we are unaware).
We also maintain a tradition of collaborative networking
with most of these resources, with inter-team contacts of-
ten initiated at conferences and/or NC-IUPHARmeetings.
A selection of those collaborative interactions that have
had direct technical consequences for connectivity and with
whom we have arranged reciprocity, is outlined in Table 5
(more of these are pending and we are open to new engage-
ments).
The overriding principle of collaborative cross-
referencing is complementarity. The expansion of our
interactions with GPCRDB during 2014/15 exemplifies
this, since both resources have had historically overlapping
engagement with the human GPCR repertoire (29,30).
This has now evolved into collaborative strategic curatorial
divergence, while at the same time offering users differen-
tial features for the 365 human Swiss-Prot IDs we have
in common. In general, this is manifested by quantitative
ligand mapping and major clinical variant collation on
the GtoPdb side, complemented by the emphasis on
sequence/structure relationships on the GPCRDB side,
which includes data on engineered substitution variants. In
addition, we are in the process of harmonising both our
web services to make it easier for users to make entity and
data joins between the two resources.
Journal-to-database connectivity
We have three initiatives in this area. The first of these is the
production of the Concise Guide to PHARMACOLOGY
(CGTP), published online as a series of PDF documents
(and in HTML) at two-yearly intervals as a supplement in
the British Journal of Pharmacology (BJP). CGTP provides
succinct overviews of families of drug targets in the form
of a desktop reference guide. The first of these appeared in
2013 (31), with the second due for publication in November
2015. Thus, targets and ligands specified in the CGTP arti-
cles online are hyperlinked directly to the database records
for users to navigate. To achieve this, the GtoPdb team and
the CGTP editors collaborate with the Wiley publishers on
what is, in effect, the automatic converting of (pre-tagged)
sections of the database directly into the online CGTP PDF
documents. The second initiative, also a collaboration with
the BJP, involves marking-up tables of links (ToLs) for both
regular papers and reviews (32). An example is a recent in-
vited review on epigenetic pathway targets for the treatment
of disease, which can be viewed at http://onlinelibrary.wiley.
com/doi/10.1111/bph.12848/epdf (the ToLs are on the sec-
ond page) (33). This exemplifies a ‘virtuous circle’ from our
special relationship with the BJP and NC-IUPHAR. The
invited review provided the curatorial starting point for the
capture of new ligands and targets to populate the database
and these were consequently surfaced as ToLs in the article.
The third journal-to-database initiative is a logical exten-
sion of the previous two (32). This involves an updated ver-
sion of the BJP instructions-to-authors that now includes
recommendations on resolving the molecular identities of
targets and ligands at the submission stage. The eventual
surfacing of such ‘curation-ready’ manuscripts will expedite
not only our capture of new database records, but also im-
proved coverage for the ToLs.
EXTERNAL PROFILE (NON-JOURNAL)
We continue to circulate our NC-IUPHAR newsletter that
includes in-depth articles on various aspects of the database.
In addition, we use various social media portals for out-
reach, updating existing users, announcing IUPHAR re-
views and other publications and sharing upcoming meet-
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Table 5. Examples of links where we have direct interactions with the database teams
Resource Connectivity Comments Reference
BindingDB Comprehensive ligand-target database, we now cross-reference selected patent
extractions from this source
(43)
ChEMBL and UniChem Inclusion of our target protein pointers and a ChEMBL look-up for our ligand
entries loaded in UniChem
(2,44)
DrugBank Target cross-references and chemical ontology connection via an API (45)
ESTER Alpha/beta hydrolase cross-references (46)
GeneCards Gene expression and functional data aggregator (47)
GPCRDB Specific pointers to their detailed features, curation of mutations, sequence display
toolbox and residue numbering system
(48)
GUDMAP Links to proteins involved in GenitoUrinary (GU) tract development (49)
HGNC Long standing and frequent interactions on target family nomenclature issues (10)
IMGT/mAb-DB Pointers to provenanced sequences for clinical antibodies, target interactions, display
tools and residue numbering system
(50)
MEROPS Feature details, classification, ligand mapping, other protease-specific issues (7)
neXtProt Data and features additional to Swiss-Prot, semantic mining technology (51)
NURSA Detailed NHR information including transcriptome mining functionality (52)
Orphanet Unique rare genetic disease curation and disease term connectivity (53)
PubChem Covering aspects of chemical curation, drug naming and our submitted structures.
Plans for future peptide and BioAssay Links
(4,14)
UniProtKB Maintenance of our own selectable cross-references to proteins with quantitative
interactions
(5)
Wikipedia Updating, adding new target and ligand links, including filling in ‘chemistry boxes’ (54)
ing presentations. We also find these outlets valuable
for occasional rapid technical exchanges with collaborat-
ing databases. Our blog (http://blog.guidetopharmacology.
org/) includes detailed release descriptions, new features,
and technical ‘how to’ items. One of us (CS) maintains an
individual technical blog where GtoPdb topics are some-
times coupled by being briefly introduced in the GtoPdb
blog but expanded on in the individual posts (http://
cdsouthan.blogspot.com/). Our Slideshare account (http:
//www.slideshare.net/GuidetoPHARM) is used for sharing
slide sets and posters with the community and has proved
popular. Users will find that presentations include descrip-
tions of content, mining approaches and utilities that ex-
tend beyond what is documented on the site. We have also
added a set of generic slides which can be used by anyone
presenting or teaching on GtoPdb. As another important
part of an external profile we endeavour to regularly update
our Wikipedia pages.
CHALLENGES AND FUTURE DIRECTIONS
Recent publications continue to highlight challenges of op-
erating in the intersection of bioinformatics and chemin-
formatics (20,21,34,35). One aspect we will be addressing
arises from the statistical analysis of content. Not unexpect-
edly, this exposes some gaps and deficiencies. For example,
we have a historical ligand-capture and information density
bias towards GPCRs, ion channels andNHRs derived from
the seed content in 2011which his has persisted even though
these targets are now outnumbered by enzymes (36). This
legacy extends into the data structure. In the past, commit-
tees have input binding data frommultiple references which
has resulted in ranges being recorded in the older records for
receptors and channels (e.g. somatostatin 1–28). However,
extraction of multiple values from different papers could
not be sustained for the recent phase of expansion because,
as we move out into the target ‘long tail’, there are fewer
independent measurements available.
Another challenge we want to address concerns the
search space, formal representation and rendering (i.e. to
provide informative visualisations) for our 1981 peptide lig-
ands. These are too small for BLAST-type peptide searches
and too large for Tanimoto-based smallmolecule searching.
In addition, many have post-translational and/or synthetic
chemical modifications. This means the linear primary se-
quence we include is incomplete as a structural specification
(although we use IUPAC nomenclature for some modifica-
tions if sufficiently detailed in the papers). We have been
testing algorithmic approaches that can ameliorate some
of these problems, in particular HELM (37) and Sugar &
Splice (NextMove Software, Cambridge, UK) and look for-
ward to the launch of PubChemBiologicals towards the end
of 2015.
Our content of targets with quantitative ligand interac-
tions constitutes a de facto druggable genome. The differ-
ence is that our 1228 target interactions are supported by
data rather than possible chemical modulation beingmerely
inferred via transitive extrapolation. So where might the up-
per limit be that we could expect to achieve with our strin-
gent but successful curation model? One source of data to
address this question is Swiss-Prot where key sources of cu-
rated chemistry-to-protein mappings, including our own,
can be compared. The result is shown in Figure 8.
The union of the four sources covers 18% of the human
proteome. However, caveats (many of which are detailed in
a 2013 database comparison study (21)) indicate this figure
should be considered a maximum count. The proportion
that would match our own criteria for quantitative map-
ping is difficult to estimate, since the chemistry-to-protein
curation strategies and source selections for each database
diverge considerably. This is manifest in the relatively high
unique content of 1147 (31% of the union). While they con-
verge as a four-way intersect for only 490 proteins (13.5%
of the union), concordance between at least two sources
(i.e. the non-unique proportion) expands to 2456. Notwith-
standing, a capture goal of 2000–2500 data-supported tar-
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Figure 8. Intersects and differentials for human Swiss-Prot ID cross-
referenced source databases that curate chemistry-to-protein mappings.
Data were generated via the UniProtKB interface and the diagram pre-
pared using the Venny tool (http://bioinfogp.cnb.csic.es/tools/venny/). The
union of all four sets is 3603, based on the Swiss-Prot ID cross-references
from UniProtKB release 2015 07.
gets for GtoPdb seems plausible. This number is particu-
larly relevant to the ‘Illuminating the Druggable Genome
(IDG) Program’ recently launched by the National Insti-
tutes of Health (NIH) (https://commonfund.nih.gov/idg/
index). This is designed to expand our understanding (and
drug targeting possibilities) of thinly annotated GPCRs,
NHRs, ion channels and kinases. This specifically applies to
‘orphans’ within those classes hitherto without good chem-
ical probes for function. The fit with our objective is clear.
However, it remains to be seen, when and what data will
surface that could be of use for curatorial expansion of the
druggable genome within GtoPdb.
We plan to add enhanced query building functionality to
the website allowing users to paste in lists of identifiers to re-
trieve targets and ligands, to choose their selection of output
fields and build customised downloads. This will be accom-
panied by development of new browsing options and alter-
native entrance portals presenting a subset of the data but
linked to the main database and designed for specific target
audiences. One such example would combine information
on targets, diseases and drugs relevant to immunology with
tools to access pharmacological data. Furthermore, we are
exploring options for providing access to our data in Re-
source Description Framework (RDF) format, which can
be readily integrated in semantic web projects such as Open-
PHACTS (38).
DATA ACCESS
GtoPdb is available online at http://www.
guidetopharmacology.org under the Open Data
Commons Open Database License (ODbL)
(http://opendatacommons.org/licenses/odbl/), and
its contents are licensed under the Creative Com-
mons Attribution-ShareAlike 3.0 Unported license
(http://creativecommons.org/licenses/by-sa/3.0/). In-
formation on linking to our pages is provided at
http://www.guidetopharmacology.org/linking.jsp. We
aim for three database public releases per year: the statistics
quoted in this paper are from release 2015.2 (i.e. August
2015). The number of entries we deprecate between releases
is low, but in rare instances an entry revision could result in
a dead link in a past release. Our downloadable files include
all target lists, NC-IUPHAR nomenclature, synonyms,
genetic information, protein identifiers and other database
accessions. Ligand downloads include isomeric SMILES
and InChI strings that can be used to generate structure-
data (SD) files. We can be contacted regarding other file
formats or some of the custom data slices specified in recent
slide presentations (enquiries@guidetopharmacology.org).
Users can also download our UniProtKB and HGNC
cross-links. A simple PubChem query (‘IUPHAR/BPS
Guide to PHARMACOLOGY’[SourceName]) will retrieve
our entire CID content (those wishing to source our local
database links for these should use the corresponding SID
query). The PubChem records should be synced within
approximately two weeks of our release date but note it
may take a little longer for all pre-computed relationships
to be fully indexed.
To further facilitate distribution, we have developed
an application program interface (API) in the form of
REST web services to provide computational access to the
data. This uses JavaScript Object Notation (JSON) as a
lightweight data-interchange format that is simple for hu-
mans to read and write as well as for machines to parse and
generate. JSONcan be readily integrated into otherwebsites
using JavaScript. In the past, we have made an SQL dump
file for download. This remains available but in response to
user requests we have added a MySQL (Oracle Corpora-
tion, Redwood Shores, CA, USA) version migrated from
PostgreSQL (http://www.postgresql.org/). This was created
using MySQL Community Server version 5.6 on Windows,
and the migration conducted withMySQLWorkbench 6.2.
Note that usage requires UTF-8 4-byte support using the
utf8mb4 character set. We also plan to enhance our Entity
Relationship Diagram for advanced users.
Since our 2014 publication, we have noted that our con-
tent has been integrated into various academic resources in-
cluding CARLSBAD (39) and ChemProt 2.0 (40). In ad-
dition, we have also been informed of incorporation into
some pharmaceutical company knowledgebases, such as the
AstraZeneca internal Chemistry Connect system (Dr Pla-
men Petrov, personal communication) (41). We would ask
groups (academic or commercial) interested in incorporat-
ing our data into their own resources, to contact us at the
outset of their integration process so that we can assist with
any technical issues that might arise on our side. The retire-
ment of IUPHAR-DB (the precursor of GtoPdb) over two
years ago (42) still produces global persistence and propaga-
tion problems. Redirects have been applied wherever possi-
ble, but users need to be circumspect if they come across sec-
ondary sources that still include IUPHAR-DB identifiers (if
you notify us we can contact the parties concerned about
substituting GtoPdb links).
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CITING THE RESOURCE
Please cite this article rather than previous ones; citation
advice for specific target pages appears on the website.
Please refer to our resource on first mention by the full cor-
rect name (IUPHAR/BPS Guide to PHARMACOLOGY)
including the capitalisation. For subsequent abbreviation,
please use GtoPdb and specify the release version number.
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We dedicate this paper to the late Professor Emeritus An-
thony J. Harmar (1951–2014), the founder of this resource.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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